Targeting microglia in brain disorders

The heterogeneity of brain immune cells could be exploited therapeutically When the neuroscientist Pío del Río Hortega first characterized “microglia” in 1919 using silver carbonate staining of animal and human brain tissues, he was impressed by the morphological plasticity and capacity to phagocyto...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2019-07, Vol.365 (6448), p.32-33
Main Authors: Priller, Josef, Prinz, Marco
Format: Article
Language:English
Subjects:
Aging
Animal tissues
Brain
Brain Diseases - immunology
Brain Diseases - therapy
Effector cells
Humans
Macrophages - immunology
Microglia
Microglia - immunology
Molecular biology
Neuroimaging
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor - antagonists & inhibitors
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor - genetics
Therapeutic applications
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The heterogeneity of brain immune cells could be exploited therapeutically When the neuroscientist Pío del Río Hortega first characterized “microglia” in 1919 using silver carbonate staining of animal and human brain tissues, he was impressed by the morphological plasticity and capacity to phagocytose (ingest) of the resident immune effector cells, called microglia ( 1 ). A century later, technological advances in molecular biology, imaging, and single-cell analysis have provided fascinating insights into the dynamic changes of microglia in response to aging and brain diseases, revealing their potential as therapeutic targets.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.aau9100